Feed NONOF
NO

Novo Nordisk A/S

NONOF · OTC

$39.70 -4.96% (-$2.07)
1M -9.03%
Market Cap 1.23T kr
P/E Ratio 10.59x
Div. Yield 4.22%
ROE 59.09%

Bulios Fair Price

$45.09

13.6% upside

Trenutna cena

$39.7

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica NONOF trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Odkleni pošteno ceno

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
6/9
Valuation
73 /100
Cheap
P/E 10.59x
EV/EBITDA 7.42x
P/S 3.74x
Growth
78 /100
Growing
EPS growth 23.43%
Rev. growth 20.34%
FCF growth 2.84%
Profitability
100 /100
Strong
Gross margin 80.69%
Net margin 35.35%
Op. margin 43.16%
Quality
92 /100
Excellent
ROIC 29.73%
ROE 59.09%
ROA 19.56%
Debt
61 /100
Moderate
Debt/Equity 0.63x
Current ratio 0.87x
Int. coverage -168.51x
Stability
48 /100
Moderate
Beta 0.35x
Rev. volatility 13.05%
EPS volatility 90.00%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o NONOF
Online

O podjetju

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark, primarily known for its innovative products and treatments for diabetes. Founded in 1923, the company has grown to become a leader in insulin products as well as medications for obesity and other chronic diseases, such as hemophilia and growth disorders. Novo Nordisk operates globally, distributing its products in over 170 countries worldwide.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Maziar Mike Doustdar

Employees

68,794

Headquarters

Bagsvaerd

Prihajajoči dogodki

04 NOV.

Earnings

Upcoming earnings report

44d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.